Afuresertib hydrochloride is under clinical development by Laekna Therapeutics Shanghai and currently in Phase II for Squamous Non-Small Cell Lung Carcinoma. According to GlobalData, Phase II drugs for Squamous Non-Small Cell Lung Carcinoma have a 17% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Afuresertib hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Afuresertib hydrochloride overview

Afuresertib hydrochloride (GSK2110183, ASB-183) is under development for the treatment of solid tumors, metastatic castration resistant prostate cancer, HR+/HER2- breast cancer, triple-negative breast cancer, ovarian clear cell carcinoma, fallopian tube cancer, primary peritoneal cancer, ovarian carcinosarcoma and ovarian sarcoma. The drug candidate is administered orally. It is an inhibitor of the serine/threonine protein kinase Akt (protein kinase B). It was also under development for ovarian cancer, fallopian tube cancer, peritoneal cancer, gastric cancer, gastroesophageal junction carcinoma and relapsed multiple myeloma, metastatic castration-resistant prostate cancer (mCRPC), breast cancer, renal cell carcinoma, non-small cell lung cancer, colorectal cancer, melanoma, head and neck cancer, pancreatic cancer, bladder cancer, hepatocellular cancer, endometrial cancer, refractory multiple myeloma and Langerhans cell histiocytosis and solid tumors and hematological tumors including relapsed or refractory chronic lymphocytic leukemia (CLL), cervical cancers like cervical squamous cell carcinoma, adenosquamous carcinoma, adenocarcinoma, endometrial cancers like endometrioid adenocarcinoma, high-grade serous carcinoma, or clear cell carcinoma, metastatic esophageal squamous cell carcinoma or Her2-negative adenocarcinoma, NSCLC (squamous cell carcinoma or adenocarcinoma, adenosquamous carcinoma), gastric adenocarcinoma and esophagogastric junction adenocarcinoma.

Laekna Therapeutics Shanghai overview

Laekna Therapeutics Shanghai, a biotech company that focused on innovative drug discovery and development. The company is headquartered in China.

For a complete picture of Afuresertib hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.